Macrolide therapy is associated with reduced mortality in acute respiratory distress syndrome (ARDS) patients.

Simonis, Fabienne D; de Iudicibus, Gianfranco; Cremer, Olaf L; Ong, David S Y; van der Poll, Tom; Bos, Lieuwe D; Schultz, Marcus J

Simonis, Fabienne D; de Iudicibus, Gianfranco; Cremer, Olaf L; Ong, David S Y; van der Poll, Tom; Bos, Lieuwe D; Schultz, Marcus J.

Afiliação

Simonis FD; Department of Intensive Care, Academic Medical Center, Amsterdam, The Netherlands.
de Iudicibus G; Laboratory for Experimental Intensive Care and Anesthesiology (L.E.I.C.A.), Academic Medical Center, Amsterdam, The Netherlands.
Cremer OL; Anesthesia and Intensive Care Unit, University of Bari Aldo Moro, Bari, Italy.
Ong DSY; Department of Intensive Care Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.
van der Poll T; Department of Intensive Care Medicine, University Medical Center Utrecht, Utrecht, The Netherlands.
Bos LD; Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands.
Schultz MJ; Center for Experimental and Molecular Medicine (C.E.M.M.), Academic Medical Center, Amsterdam, The Netherlands.

Ann Transl Med ; 6(2): 24, 2018 Jan.

Article em En | MEDLINE | ID: mdl-29430441

Palavras-chave

Acute respiratory distress syndrome (ARDS); erythromycin; macrolide; mortality; phenotypes; propensity score

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Revista: Ann Transl Med Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Holanda País de publicação: China

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google